Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 2 for:    itind meditate
Previous Study | Return to List | Next Study

A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03994263
Recruitment Status : Terminated (low recruitment)
First Posted : June 21, 2019
Last Update Posted : October 7, 2021
Information provided by (Responsible Party):
Medi-Tate Ltd.

Brief Summary:
A total of up to 15 eligible subjects will be enrolled into this open-labeled one-arm study designed to observe the mechanism of action of iTind when using MRI

Condition or disease Intervention/treatment Phase
BPH Device: ITind device implant Not Applicable

Detailed Description:

Study Objective:

To validate the iTind efficacy by using MRI in subjects with symptomatic BPH. Specifically the pressure points created by the iTind's struts and its implications on blood flow to the prostate will be assessed.

Efficacy Endpoints:

The endpoints of this study are:

  • Decrease in transition zone volume
  • Monitor size and location of ablative lesions
  • Monitor change in time of lesions
  • Monitor the correspondence change in prostate tissue All the above will be assessed by using MRI.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot and Prospective Study to Observe the Mechanism of Action of Medi-Tate i-Temporary Implantable Nitinol Device (iTind) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH) With Magnetic Resonance Imaging (MRI)
Actual Study Start Date : November 18, 2019
Actual Primary Completion Date : February 18, 2021
Actual Study Completion Date : February 18, 2021

Arm Intervention/treatment
Experimental: iTind arm
ITind device implant
Device: ITind device implant
device implanted for 5-7 days

Primary Outcome Measures :
  1. AE rate [ Time Frame: 12 months ]
    Incidence (% of subjects) and frequency (no. of events) of device related adverse events.

  2. Unexpected SAE [ Time Frame: 12 months ]
    Incidence (% of subjects) and frequency (no. of events) of unexpected serious adverse events deemed as related to Meditate iTIND and/or to implantation/retrieval procedures.

  3. Device complications [ Time Frame: 12 months ]
    Incidence (% of subjects) and frequency (no. of events) of Meditate iTIND and/or to implantation/retrieval procedures complications

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Male with symptomatic BPH
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject signed informed consent form (ICF)
  • Age 40 and above- Male with symptomatic BPH.
  • IPSS symptom severity score ≥ 13
  • Peak urinary flow of < 12 ml/sec
  • Prostate volume between 25 ml to 80 ml (assessed by pre-operative ultrasound - TRUS)
  • Blood CBC and biochemistry up to two weeks before screening, demonstrating: Normal values of the PT, PTT and INR tests (Anticoagulants washout may be done two weeks prior of device implantation)
  • Subject able to comply with the study protocol
  • Normal urinalysis and negative urine culture
  • Subjects that are able to undergo MRI.

Exclusion Criteria:

  • A post void residual (PVR) volume > 250 ml measured by ultrasound or acute urinary retention
  • Confirmed or suspected bladder cancer;
  • Recent (within 3 months) cystolithiasis or hematuria;
  • Urethral strictures, bladder neck contracture, urinary bladder stones or other potentially confounding bladder pathology;
  • An active urinary tract infection.
  • Enrolled in another treatment trial for any disease within the past 30 days.
  • Previous colo- rectal surgery (other than hemorrhoidectomy) or history of rectal disease if the therapy may potentially cause injury to sites of previous rectal surgery, e.g., if a transrectal probe is used;
  • Previous pelvic irradiation, cryosurgery or radical pelvic surgery;
  • Previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate
  • Median lobe obstruction of the prostate (larger than 1cm).
  • Cancer that is not considered cured, except basal cell or squamous cell carcinoma of the skin (cured defined as no evidence of cancer within the past 5 years)
  • Patient with renal dysfunction
  • Any serious medical condition likely to impede successful completion of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03994263

Layout table for location information
Kliniken Nordoberpfalz AG Klinik für Urologie, Kinderurologie und interdisziplinäres Prostatakarzinomzentrum
Weiden, Germany
Sponsors and Collaborators
Medi-Tate Ltd.
Layout table for investigator information
Principal Investigator: Thomas Bschleipfer, Prof. Weiden Clinic
Layout table for additonal information
Responsible Party: Medi-Tate Ltd. Identifier: NCT03994263    
Other Study ID Numbers: MT-09
First Posted: June 21, 2019    Key Record Dates
Last Update Posted: October 7, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No